SUBJECT INDEX TO VOLUME 44

(±)-Huprine Y, 749
(±)-Huprine Z, 749
17β-Estradiol, 584
2,3 DHBA, 2,3 dihydroxybenzoic acid, 787
2,5 DHBA, 2,5 dihydroxybenzoic acid, 787
3,4-methylenedioxymethamphetamine, 439
4-AP, 4-aminopyridine, 686
40 Hz oscillations, 864
5-choice serial reaction time task, 324
5-CT, 1031
5-CT, 5-carboxamidotryptamine, 873
5-HT, 893
5-HT, 5-hydroxytryptamine, 431
5-HT, 5-hydroxytryptamine (serotonin), 873
5-HT1A, 893
5-HT1A receptor, 562, 873
5-HT7 receptor, 1031
5-HT_{1A} receptor, 206
5-HT_{1A} receptors, 93
5-HT_{1A}, 5-HT_3, 1022
5-HT_{2A} receptor function, 911
5-HT_{2A} receptors, 604
5-HT_{2C} receptor, 439
5-HT_{2C} receptor function, 911
5-HT_{3A}, serotonin type 3A, 431
5-HT_3 receptors, 214
5-Hydroxytryptamine, 214, 431
5-Hydroxytryptamine (5-HT) release, 367
5α-reductase, 49
606, 324
8-Br-cAMP, 8-bromo-cyclic-3′,5′-adenosine monophosphate, 686
8-OH-DPAT, 8-(hydroxy-2-(di-n-propylamino)tetralin, 873
[^{35}S]GTPγS autoradiography, 93
[^{3}H]glutamate binding, 199

A

A-437203, 1047
ABT-418, 1054
AC, adenylyl cyclase, 686
Acetylcholine, 40
ACh, acetylcholine, 765
AChE inhibitor, 749
ACSF, artificial cerebral-spinal fluid, 493
Addiction, 926
Adenosine, 686
Adenosine 3′,5′-cyclic monophosphate, 672
Adenylyl cyclase, 686
Agarose, 817
Aggregation, 403
Aggression, 911
Aging, 381
Akt, 482

SUBJECT INDEX TO VOLUME 44

(±)-Huprine Y, 749
(±)-Huprine Z, 749
17β-Estradiol, 584
2,3 DHBA, 2,3 dihydroxybenzoic acid, 787
2,5 DHBA, 2,5 dihydroxybenzoic acid, 787
3,4-methylenedioxymethamphetamine, 439
4-AP, 4-aminopyridine, 686
40 Hz oscillations, 864
5-choice serial reaction time task, 324
5-CT, 1031
5-CT, 5-carboxamidotryptamine, 873
5-HT, 893
5-HT, 5-hydroxytryptamine, 431
5-HT, 5-hydroxytryptamine (serotonin), 873
5-HT1A, 893
5-HT1A receptor, 562, 873
5-HT7 receptor, 1031
5-HT_{1A} receptor, 206
5-HT_{1A} receptors, 93
5-HT_{1A}, 5-HT_3, 1022
5-HT_{2A} receptor function, 911
5-HT_{2A} receptors, 604
5-HT_{2C} receptor, 439
5-HT_{2C} receptor function, 911
5-HT_{3A}, serotonin type 3A, 431
5-HT_3 receptors, 214
5-Hydroxytryptamine, 214, 431
5-Hydroxytryptamine (5-HT) release, 367
5α-reductase, 49
606, 324
8-Br-cAMP, 8-bromo-cyclic-3′,5′-adenosine monophosphate, 686
8-OH-DPAT, 8-(hydroxy-2-(di-n-propylamino)tetralin, 873
[^{35}S]GTPγS autoradiography, 93
[^{3}H]glutamate binding, 199

A

A-437203, 1047
ABT-418, 1054
AC, adenylyl cyclase, 686
Acetylcholine, 40
ACh, acetylcholine, 765
AChE inhibitor, 749
ACSF, artificial cerebral-spinal fluid, 493
Addiction, 926
Adenosine, 686
Adenosine 3′,5′-cyclic monophosphate, 672
Adenylyl cyclase, 686
Agarose, 817
Aggregation, 403
Aggression, 911
Aging, 381
Akt, 482

Alpha-2 agonists, 739
Alzheimer's disease, 749
AM-36, 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1-dimethyl)-4-hydroxyphenyl)methylpiperazine, 787
Aminoguanidine, 253
AMPA, 163, 462, 801
AMPA receptor, 70
AMPA receptor potentiator, 1013
AMPA receptors, 81, 88
Amphetamine, 717
Amygdala, 516, 926, 1068
Analgesia, 264
Analgesic, 413
Animal models, 234
Anion-selective, 431
Anisotropy, 642
Anoxia/reoxygenation, 642
Anticonvulsant, 413
Antidepressant, 562, 616, 801, 893, 1013
Antidepressants, 903
Antinociception, 304
Antipsychotics, 604
Anxiety, 367, 516
Anxiolytic, 562
Apoptosis, 482
Appetite, 264
Approach-avoidance, 473
AR-R17779, 1054
Arc, 893
Arf, 171
ASIC3, 662
Astrocytes, 171
ATP, 132
Attention, 1054
Audiogenic seizures, 275
Autoradiography, 111
AVP_{4-9}, 541
Axonal transport, 1107

B

BAPTA, 1,2-*bis*(aminophenoxy)-ethane-*N*,*N*,*N*,*N*′-tetraacetic acid, 493
BDNF, brain-derived neurotrophic factor, 482
Behavioral sensitization, 102
Behaviour, 253, 592, 616
Benzodiazepine receptors, 111
BIC, (−)-bicuculline methochloride, 765
Bicuculline, 157
BK channels, 855
Blood pressure, 757
Body temperature, 1047
Brain, 413
Brain slice, 49
Brain-derived neurotrophic factor (BDNF), 903
BrdU, 5-Bromo-2′-deoxy-uridine, 482
Brefeldin A, 1107
Bungarotoxin, 224

C
C-fos, 264
Ca^{2+}-binding protein, 707
Calcium, 686
Calcium imaging, 141, 214
Calcium mobilization, 141
Calcium pools, 390
CaMKII, Vesicle mobilization, 390
cAMP, 141, 686, 1038
cAMP, cyclic-3′,5′-adenosine monophosphate, 686
cAMP-dependent protein kinase, 686
Cannabinoid, 264
Capsaicin, 958
Capsiate, 958
Caspase, 1068
Cation-selective, 431
Ca^{2+}, 132, 541
Ca^{2+} oscillations, 855
Ca^{2+} response, 873
CCh, carbachol, 40
CCK receptor antagonists, 524
Central sensitization, 423
Cerebral blood flow, 653
cFos, 1089
CHA, N^6-cyclohexyladenosine, 686
Chick L247T/C189–190Sα7 mutant, 765
Chick L247Tα7 mutant, 765
CHO, Chinese hamster ovary, 873
Cholecystokinin, 524
Cholinergic, 224
Cholinesterase inhibitor, 381
Chronic constriction injury, 983
Cingulate cortex, 757
Clonidine, 739
Clozapine, 604
CLT, chelerythrine, 493
Cocaine, 342
Cognition, 324
Cognitive function, 845
Conjugated 17β-estradiol, 584
Consciousness, 864
Cortical neurons, 482
Cortical spreading depression, 949
Corticosterone, 555
COX-2, 374
CP101, 324
CREB, 26
Cultured sympathetic neurons, 1107
Cyclin-dependent kinase 5, 1089
Cytisine, 503

D
D2 receptor, 354
D4 agonist, 473
DA, dopamine, 787
DAMGO, [d-Ala^2, *N*-Me-Phe^4, Gly^5-ol]enkephalin, 482

Delayed match to position, 324
Delayed response task, 381
Dentate gyrus, 374
Depression, 516, 616
Descending modulation, 983
Desensitization, 132, 699
Development, 181
Diazepam, 190
dihydro-β-erythroidine (DHβE), Nicotine, methyllycaconitine (MLA), 367
DMEM, Dulbecco's modified Eagle's medium, 482
DMSO, dimethysulfoxide, 431
DOI, 911
DOPAC, 3,4-dihydroxyphenylacetic acid, 787
Dopamine, 190, 354, 449, 633, 717, 926
Dopamine antagonists, 199
Dopamine D2 receptors, 102
Dopamine D4 receptors, 1038
Dopamine microdialysis, 342
Dopamine receptors, 81
Dorsal hippocampus, 367
Dorsal raphe nucleus, 206
Dorsal root ganglion, 132, 141
DPCPX, 8-cyclopentyl-1,3-dipropylxanthine, 686
DRG neuron, 662
DRL, 324
Drug addiction, 102
Drug discrimination, 604
D_1 receptor, 1047
D_2 receptor, 1047
D_2 receptors, 604
D_3 receptor, 1047

E
Ecstasy, 449
Efficacious and partial agonists, 873
EGTA, ethylene glycol-bis((-aminoethyl ether) N,N,N',N'-tetra acetic acid, 431
Eight-arm radial maze, 533
Electroconvulsive shock, 911
Electroencephalogram, 1068
Electroencephalograph, 234
Electrophysiology, 8
Elevated plus-maze, 439
Ensemble recording, 633
Enteric nervous system, 524
Epibatidine, 1054
Epilepsy, 157, 234, 1068
ERK, extracellular signal-regulated kinase, 482
ET-1, endothelin-1, 787
Ethanol withdrawal, 275
EtOH, ethanol, 493
Excitability, 1
Excitatory amino acids, 811
Excitotoxicity, 117

F

F 13640, N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methylpyridin-2-yl)-methylaminomethyl] pipe-ridine, 873
F 14679, N-(3-chloro-4-fluorobenzoyl)-4-fluoro-4-[(5-methyl-6-methylamino pyridin-2-yl)-methylaminomethyl]-piperidine, 873
Fasting, 199
FCS, fetal calf serum, 482
Fear conditioning, 1089
Fiber volley, 26
Fluoxetine, 93, 342
Fluvoxamine, 342
FMRFamide-related neuropeptides, 662
Focal ischemia, 787
Focal stimulation, 1022
Food intake, 199
Foot drumming, 516
Forced swimming test, 616
Fos, 264
Frequency facilitation, 968
Freshly isolated neurons, 493
Frontal cortex, 584
Fusion protein, 873

G

G protein-coupled inward rectifier potassium channels, 699
G protein-coupled receptor kinase, 699
G proteins, 93
GABA, 163, 190, 304
GABA release, 1022
GABA, γ-aminobutyric acid, 493
GABA, γ-aminobutyric acid, 431
$GABA_A$ antagonists, 994
$GABA_A$ partial agonists, 994
$GABA_A$ receptor, 49, 864
$GABA_A$ receptor–ionophore complex, 994
$GABA_A$, type A GABA receptor, 431
$GABA_C$, type C GABA receptor, 431
Galanin, 206
GC cell culture, 672
Gender differences, 624
Gene targeting, 882
General anaesthesia, 864
Glu-Cl, glutamate-gated Cl^- channel, 431
Glutamate, 8, 88, 171, 717
Glutamate release, 282, 390, 686
Glutamate-sensitizing activity, 117
Glutathione peroxidase, 449
Gly, glycine, 493
Golgi, 1107
Golgi cell, 181
GPCR, 773
GPCR mutations, 125
GPCR, G protein-coupled receptor, 482
GPCR, G-protein-coupled receptors (GPCRs), 686
Granule cell, 181
Growth hormone, 672

GST pull-down, 817
Guanabenz, 739

H
Halocytisines, 503
Halogenated ethers, 811
HEK 293 cells, 829, 1003
Hemorrhagic shock, 244
HEPES, N-2-hydroxyethylpiperazine-N-2-etanesulfonicacid, 431
High extracellular potassium, 949
Hippocampal neurons, 707
Hippocampus, 17, 40, 206, 282, 584, 592, 845, 903, 968, 1013, 1068, 1089
Histamine H_3 receptor, 773
HU210, 633
Human L248Tα7 mutant, 765
Huperzine A, 749
HVA, 4-hydroxy-3-methoxy-phenylacetic acid, 787
Hyperalgesia, 983
Hyperpolarization-activated cation channel (I_h channel), 968
Hypertension, 757
Hypoglycemia, 199
Hypothalamic–pituitary–adrenal axis, 555
Hypothalamus, 264, 845, 940
Hypothermia, 1031
Hypothyroidism, 111
Hypoxia, 801

I
IBMX, 3-isobutyl-1-methylxanthine, 686
ICL, intracellular loop, 873
Immunoprecipitation, 817
Impulsivity, 324
In situ patch–clamp, 49
iNOS inhibitor, 244
InsP3 receptors, 390
Insulin, 855
Interictal-like activity, 157
Interleukin-1β, 801
Intracellular calcium, 282
Intracellular Ca^{2+}, 672
Ion channel blocker, 413
Ion channels, 845
Ionic homeostasis, 949
IPSCs, 181
Isoarecolone, 1054
I_{Gly}, glycine current, 493
I_h, 293

K
Ketamine, 729
Knock-out, 190
KO mice, 653
Kv1.1, 829
K_{ATP} channels, 855

L
L-741,626, 1047
L-750667, 1038
L-NAME, 533
L247T, chick L247Tα7 mutant, 765
L247T–C189S–C190S, chick L247T/C189–190Sα7 mutant, 765
L248T, human L248Tα7 mutant, 765
Lateral fluid-percussive brain injury, 253
Leak channels, 1
Leptin, 845
LGIC, ligand gated ion channels, 431
Ligand-gated ion channel, 431
Limbic system, 157, 757
Locomotion, 102, 473
Locomotor activity, 342, 717
Locus coeruleus, 88
Long-term depression, 968
Long-term plasticity, 707
Long-term potentiation, 26, 968
LTD, 40, 374
LTP, 17, 40, 374
LY 367385, 8
LY451646, 1013

M
m-chlorophenylpiperazine, 439
MABP, 244
Magnetic resonance imaging, 253
MAPK, 855
MAPK, mitogen-activated protein kinase, 482
MCA, middle cerebral artery, 787
mCPP, 911
MDL100,907, 604
Medial prefrontal cortex, 462
Mediobasal hypothalamus, 354
MEK, mitogen-activated protein kinase and ERK kinase, 482
Membrane estrogen receptor, 584
Memory, 381
Metabotropic glutamate receptor, 157, 699, 983
Metabotropic glutamate receptors, 17, 293, 555, 707, 717
Metabotropic glutamate subtype-5 receptor, 423
Methimazole, 111
mGluR1 KO mice, 157
mGluR5, 562
mGluR5 KO mice, 157
Mg^{2+}, 132
Mice, 555
Microdialysis, 206, 354, 533, 592, 787, 949
Mitochondria, 642
Molecular modeling, 773
Monoclonal antibody K1C3, 829
Morphine, 304
Morphine withdrawal, 88
Mossy fiber, 968
Mouse, 1031
MPEP, 8

MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 482
Muscarinic acetylcholine receptors, 293
Muscarinic receptors, 653
Muscarinic$_1$ receptor, 541
Mutagenesis, 699, 773

N
N-methyl-**d**-aspartate, 190
nAChR, nicotinic acetylcholine receptor, 431
Naloxone, 264
NC-1900, 541
Neuroblastoma, 214
Neurochemistry, 882
Neurodegeneration, 624
Neurogenesis, 1013
Neurokinin A, 117
Neurokinin B, 117
Neuroleptics, 1100
Neurological functions, 244
Neuronal apoptosis, 253
Neuronal excitability, 845
Neuronal nicotinic receptors, 503
Neuropathy, 983
Neuropeptide Y, 282
Neuroprotection, 253, 787, 801
Neurosteroid, 49
Neurosteroids, 994
Neurotoxicity, 449, 624, 739
NGF, 390
Nicotine, 224, 642, 1054
Nicotinic, 234
Nicotinic acetylcholine receptor, 70
Nicotinic receptors, 224
Nigrostriatal, 624
Nitric oxide, 949
Nitric oxide synthase, 616, 949
NK$_1$ receptor, 516
NMDA, 163, 275, 462, 801
NMDA antagonists, 729, 739
NMDA receptor, 70
NMDA receptors, 81
NO, 533
NO donor, 949
Nociception, 132, 141, 423
Non-human primate, 381
Non-pungency, 958
Noradrenaline, 757
Novelty seeking, 473
NR2A knockout mice, 324
NS398, 374
Nucleus accumbens, 102, 342, 592, 926, 940
Nω-nitro-L-arginine methyl ester (L-NAME), 949

O
Olanzapine, 462
Olvanil, 958

Open field, 473
Opioid, 264, 482, 573
Opioid receptors, 111
Oxidative stress, 1100

P
P2X, 403
P2X receptors, 311
p38 MAPK, 374
Pain, 304, 958
Paired recording, 181
Paired-pulse facilitation, 968
Parathyroid hormone receptor 2, 141
Parkinson's disease, 624, 642
Patch-clamp, 214, 493, 829
Paw thermal stimulation, 739
PBS, phoshate-buffered saline, 482
PD 128907, 1047
Pelvic nerve, 163
Pentylenetetrazole, 234
Periaqueductal gray, 275
Periaqueductal gray neuron, 573
Peristaltic reflex, 524
pH, 403
Phencyclidine, 462
Philanthotoxin, 70
Phosphatidylinositol 3-kinase, 482
Phosphodiesterase, 686
Phospholipase C, 171
Phospholipase D, 171
Phosphorylation, 26, 493, 686, 699, 829
PI 3-K, phosphatidylinositol 3-kinase, 482
PI 3-kinase, 855
Picrotoxin, 431
PKA, cAMP-dependent protein kinase, 686
PKC phosphorylation site, 873
PKC, protein kinase C, 493, 686, 873
PKC_{ϵ}-TIP, protein kinase C_{ϵ} translocation inhibitor peptide, 493
PKC_{ϵ}-TIP-NC, protein kinase C_{ϵ} translocation inhibitor peptide negative control, 493
PLC, phospholipase C, 873
PMA, phorbol 12-myristate 13-acetate, 873
PMA, phorbol-12-myristate-13-acetate, 493
Prefrontal cortex, 926
Prepulse inhibition, 324, 729
Presynaptic G-protein-coupled receptors, 686
Presynaptic receptors, 311, 882
Progenitor cell, 1013
Programmed cell death, 1068
Prolactin, 940
Protein expression, 1003
Protein kinase A, 573, 829
Protein kinase C, 26, 171, 573, 829
Protein synthesis, 26, 707
Psychosis, 729
PTX, pertussis toxin, 482

PTX, picrotoxin, 431
PTZ, pentylenetetrazole, 431
Pudendal nerve, 163
Purinergic, 403

Q
Quercetin, 1100
Quinpirole, 102

R
RA, retinoic acid, 482
Radioligand binding, 672
Rapid agonist application, 1003
Rat, 244, 324, 423
Reactive oxygen species, 787
Receptor–receptor interaction, 206
Reinforcement, 633
Repeated ischemia, 533
Respiratory control ratio, 642
Resting potential, 1
Retina, 1038
Reward, 264
Rho, 171
RO20-1724, 4-(3-butoxy-4-methoxyphenyl) methyl-2-imidazolidone, 686
ROS, reactive oxygen species, 787
Rostral ventromedial medulla, 983
Rp-cAMPS, Rp-cyclic-3′,5′-adenosine-monophosphothioate, 686
Ryanodine receptors, 390

S
Salicylate hydroxylation, 787
Satiety signal, 845
Saturability, 653
SCH 23390, 1047
Schizophrenia, 604, 729
Scopolamine-induced convulsions, 199
Seizure, 234
Selenium, 449
Sepharose, 817
Septum, 1089
Serotonin, 206, 214, 304, 439, 449, 592, 616
Sevoflurane, 811
Sex differences, 381
Sexual receptivity, 354
SH-SY5Y cells, 482
Sheep, 354
Signal transduction, 773
Signalling pathways, 845
Single bouton, 1022
SK1, 817
SKF 105111, 49
Small intestine, 524
Social interaction, 439
Sodium channels, 413
Sp4, 1089
Spatial memory, 533, 541

Species selectivity, 773
Spectral analysis, 672
Spinal cord, 423
Spinal cord transmission, 811
Spontaneous activity, 994
SRIF receptor agonists, 672
SSRI, 893
Startle reflex, 729
STD, standard external solution, 493
Stereoisomers, 864
Strain differences, 473
Striatum, 926, 940
Superoxide anions generation, 642
Synaptic modulation, 1022
Synaptic plasticity, 8, 390
Synaptosomes, 282, 311, 686
Syntaxin, 817

T

T3 (triiodothyronine), 111
Tacrine, 749
Tamoxifen, 584
Tardive dyskinesia, 1100
Taurine, 26
TE671 cells, 70
THC, 264
The shell of the nucleus accumbens, 81
TIP39, 141
TNPA, 1047
Tonic, 275
Transgenic mice, 8
Traumatic brain injury, 224
TrkA receptors, 390
TRPV1, 958
Tuberoinfundibular, 940
Tubulin, 1107
Turning behaviour, 81

U

U-93631, [4-Dimethyl-3-t-butylcarboxyl-4,5-dihydro (1,5-a) quinoxaline], 431
U50,488, 304

V

Vasopressin, 757
Vasopressin$_{1A}$ receptor, 541
VCMs, 1100
VDCC, voltage-dependent Ca^{2+}-channels, 686
VIP, 125
VIP agonist, 125
VIP antagonist, 125
Visual cortex, 390
Voltage-dependent calcium channel, 686
Voltage-gated Ca^{2+} channel, 282
$VPAC_1$ receptor, 125
VTA, 633
VTA, ventral tegmental area, 493

W
Water maze, 324
WAY 100635, N-[2-[4-(2-methoxyphenyl)1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide, 873
Whole-cell patch clamp, 431
Whole-cell recording, 1003

X
Xenopus, 403
Xenopus oocyte, 70, 765

Z
Zinc, 403
α1, 190
α4β2 Nicotinic receptors, 503
α4β4 Nicotinic receptors, 503
α7, 224
α7 Nicotinic receptors, 503
α7-AChR, neuronal α7 nicotinic acetylcholine receptor, 765
α_1-Adrenoceptors, 604
α_2-adrenoceptor subtypes, 882
β-FNA, β-funaltrexamine, 482
γ-Aminobutyric acid, 573
γ-Aminobutyric acid (type B) receptors, 311
γ_H, high class of conductance, 765
γ_L, low class of conductance, 765
γ_M, middle class of conductance, 765
θ-rhythm, 293
τ_{bn}, exponential time constant in the burst distribution, 765
τ_b, burst duration, 765
τ_{cn}, time constant in the closed time distribution, 765
τ_c, critical time, 765
τ_{on}, time constant, 765
τ_{op}, open time, 765

AUTHOR INDEX TO VOLUME 44

Abe, K., 541
Abel, K.M, 729
Abraini, J.H., 717
Akaike, N., 1022
Akiyama, G., 81
Alcalá, M.M, 749
Allen, K.V., 264
Allescher, H.D., 524
Allin, M.P.G, 729
Alper, R.H., 584
Alvarez, L., 26
Andersen, K., 70
Anderson, J., 983
Anderson, J.J., 562
Anderson, L.I., 624
Antunes-Rodrigues, J., 757
Ashford, M.L.J., 845
Atack, J.R., 190
Austin, J.D, 102
Awaiz, S., 864

Badia, A, 749
Bagnoli, P., 672
Bai, F., 1013
Ballard, T.M., 324
Barbato, C, 117
Baron, A., 662
Bashir, Z.I., 40
Battaglia, G., 555
Beer, M.S., 1031
Bell-Horner, C.L., 431
Benfenati, F., 390
Benkwitz, C., 1003
Bennani, Y.L., 773
Bergeron, M., 1013
Berkovic, S.F., 234
Bermúdez, I., 503
Bernardi, G., 8
Biondi, C., 672
Blacker, M., 1107
Boileau, A.J., 1003
Bonanno, G., 390
Bowden, S.E.H., 817
Boyce, S., 516
Brackmann, M., 707
Bradbury, M., 983
Bradbury, M.J., 562
Braunewell, K.-H., 707
Brickley, S.G, 181
Brier, T.J., 70
Brierley, M.J., 70
Brillault, J., 801
Briones-Velasco, M., 111
Bristow, L., 983
Bromidge, F.A., 190
Brown, M.W., 40
Brown, T.C., 403
Bubar, M.J., 342
Buccafusco, J.J., 381
Bull, E.J., 439
Bulters, D.O., 293
Bustamante, J., 26
Bíró, T, 843

Calabresi, P., 8
Calissano, P, 117
Callaway, J.K., 787
Camarero, J., 449
Campenot, R.B., 1107
Camps, P, 749
Capece, A., 17
Cappuccio, I., 555
Carey, R.J., 592
Caricasole, A., 555
Carr, T.L., 773
Carvalho, A.P, 282
Carvalho, C.M, 282
Cassar, S., 773
Cassels, B.K., 503
Catania, M.V., 17
Catterall, W.A., 413
Cecchelli, R., 801
Centonze, D., 8
Cervia, D., 672
Chaperon, F., 1047
Chapman, D.F., 562
Chapman, K.L, 1038
Cheer, J.F., 633
Chesneau, D, 354
Chiechio, S., 17
Cho, J.-J., 573
Cho, Y.-W., 573
Christophersen, P, 553
Ciotti, M.T, 117
Clare, J.J., 413
Clyne, J.D., 403
Cobb, S.R., 293
Colado, M.I., 449
Colpaert, F.C., 873
Comella, J.X., 482
Conn, P.J, 699
Connor, T.J., 616
Conquet, F., 8, 157
Cook, G.P., 1031
Cools, A.R., 81
Coppell, A.L., 903
Cormier, A., 642
Corrêa, F.M.A., 757
Costa, C., 8
Costa, E., 49
Crippa, G.E., 757
Cunningham, K.A., 342
Czajkowski, C., 1003

Das, P., 431
David, H.N., 717
Davies, C.H., 293
Davies, P.A., 214
Dawson, G.R., 190
De Deurwaerdère, P., 342
De La Riva, C, 354
Debonnel, G, 554
Dekeyne, A., 604
Del Bianco, P., 555
del Olmo, E, 93
del Olmo, N., 26
Della Penna, K., 141
Deval, E., 662
Di Giorgi Gerevini, V., 555
Diaz, A, 93
Dickinson, R., 864
Dillon, G.H., 431
Dluzen, D.E., 624
Dommergues, M.-A., 801
Drago, J., 234

Eckelman, W.C., 653
Egan, E., 1031
Egashira, N., 533, 541
Eldursi, N., 70
Elena Castro, M., 93
Eng, H., 1107
Enginar, N., 199
Epelbaum, J., 672
Esbenshade, T.A., 773
Eusebi, F., 765
Exley, R., 503

Fabre-Nys, C, 354
Faingold, C.L., 275
Fairhall, S.J., 911
Farrant, M, 181
Feldon, J, 926

Ferger, B., 926
Fernandes, K.B.P., 757
File, S.E., 367
Finkelstein, D.I., 234
Fischer, A., 1089
Fisher, A., 516
Fletcher, A., 911
Fletcher, S., 817
Fone, K.C.F., 439, 1031
Franks, N.P., 864
Fujii, Y., 81
Fujiwara, M., 533, 541
Fushiki, T., 958

Geiger, J.D., 155
Genn, R.F., 367
Geyer, M.A., 473, 729
Gill, C.H., 293
Gill, R., 324
Giniatullin, R., 132
Giovedì, S., 390
Giracello, D.R., 562
Godel, T., 473
Gomeza, J., 653
Gómez-Villafuertes, R., 311
Gray, K., 893
Green, A.R., 449
Gressens, P., 801
Gualix, J., 311
Gubellini, P., 8
Guidotti, A., 49
Guscott, M.R., 1031
Gutkind, J.S., 171

Hahm, E.-T., 573
Hahn, A., 524
Hahn, B., 1054
Hales, T.G., 214
Hama, A.T., 423, 983
Han, S.-H., 573
Hancock, A.A., 773
Handler, A., 26
Harkin, A., 616
Hartman, D.S., 473
Hartmann, S., 1031
Harvey, J., 845, 855
Hashizume, S., 958
Haughey, N.J., 155
Hemsley, D.R., 729
Herget, T., 829
Hernández-Garcia, A., 111
Higgins, G.A., 324
Hinton, M.R., 354
Holtz, G., 562
Horne, M.K., 234
Hospital, S., 749
Houlihan, L.M., 503
Hoyer, D., 672
Hsu, K.-S., 968
Huang, C.-C., 968
Hume, R.I., 403
Hunt, G.E., 264
Huston, J.P., 592
Hutchins, C.W., 773
Hutson, P.H., 1038
Hutson, P.H., 439, 1031
Huwyler, J., 324

Iglesias, M., 482
Iida, T., 958
Ikeda, H., 81
Inada, K., 541
Iob, L., 604
Iwasaki, K., 533, 541

Jackson, W.J., 381
Jagoda, E.M., 653
Jardemark, K.E., 462
Jaroszewski, J.W., 70
Jarrott, B., 787
Jensen, B.S., 553
Jespersen, T., 553
Jevtovic-Todorovic, V., 739
Jiang, Z.L., 493

Kaneko, T., 533
Kato, G., 801
Katsurabayashi, S., 1022
Kehr, J., 206
Kelly, J.P., 616
Kemp, J.A., 324
Kendall, D.A., 633
Kendrick, K.M., 354
Kiesewetter, D.O., 653
Kinose, F., 141
Kirkness, E.F., 214
Klink, R., 554
Kobata, K., 958
Koblan, K.S., 141
Koeltzow, T.E., 102
Koshikawa, N., 81
Koyuncuoğlu, H., 199
Krogsgaard-Larsen, P., 70
Kubota, H., 1022
Kulagowski, J., 1031
Kulkarni, S.K., 1100
Kulla, A., 17

Lagrue, G., 642
Langenegger, D., 672
Langer, I., 125
Larkman, P.M., 293
Lawrence, A.J., 787
Lazdunski, M., 662
Lähdesmäki, J., 882
Lee, J.-J., 573
Lesage, F., 1
Li, T., 1003
Lieb, W.R., 864
Lin, T.-B., 163
Ling, E.A., 253
Lingueglia, E., 662
Liu, G., 413
Locatelli, A., 354
Long, C., 275
Lopez-Garcia, J.A., 811
Low, S.Y., 244
Lu, J., 244, 253
Lukas, R.J., 503
Lund, K., 1107

MacDonald, E., 882
Machu, T.K., 431
MacInnis, B.L., 1107
Maksay, G., 843, 994
Mallet, P.E., 264
Malva, J.O., 282
Manahan-Vaughan, D., 17, 707
Marrion, N.V., 817
Marsden, C.A., 633
Marston, D., 1038
Martín del Río, R., 26
Masgrau, R., 171
Maskell, P.D., 503
Mason, R., 633
Massey, P.V., 40
Masters, J.N., 773
Matrisciano, F., 555
Matsumoto, K., 49
Matsumoto, Y., 541
Matthias, K., 829
Matute, E., 811
Mazarguil, H., 662
McAllister, G., 1031
McColl, C.D., 234
McGregor, I.S., 264
McMahon, L.R., 342
Md, S., 244
Melchiorri, D., 555
Mellor, I.R., 70
Mercanti, D., 117
Meyenburg, A.P., 739
Mienville, J.-M., 49
Miledi, R., 765
Millan, M.J., 604

Min, B.-I., 573
Minowa, R., 81
Miras-Portugal, M.T., 311
Mishima, K., 533, 541
Mitchell, P.J., 911
Miura, I., 541
Mize, A.L., 584
Mogil, J.S., 304
Moochhala, S, 253
Moochhala, S.M, 244
Moore, X.L, 253
Morin, C., 642
Morita, A., 958
Moriyama, T., 958
Muñoz-Torrero, D, 749
Muñoz, C., 801
Murayama, N., 958
Murphy, C.A, 926
Murray, H.J., 374
Müller, C.P., 592
Myers, R.E., 624

Naidu, P.S, 1100
Narkilahti, S., 1068
Neijt, H.C., 1047
Nelson, D.L., 1013
Nemmani, K.V.S., 304
Newman, R.J., 190
Newson, M., 893
Ng, K.C, 244, 253
Ngomba, R.T., 17
Nicoletti, F., 17, 555
Ninan, I., 462
Nissinen, J., 1068
Nistri, A, 132
Nobbs, M., 413
Nurten, A., 199
Nurten, R., 199

Obrenovitch, T.P., 949
Ohkura, S, 354
Olesen, S.-P, 553
Oliver, L., 293
Olmos, G., 482
Olney, J.W., 739
Ortiz-Butron, R., 111
Othman, T., 155
O'Connor, J.J., 374
O'Malley, D, 855
O'Meara, G.F., 190
O'Shea, E., 449
Ögren, S.O., 206

Pacheco-Rosado, J., 111
Palma, E., 765
Pardo, R, 171
Parkinson, F.E., 155
Passarelli, F., 17
Patel, S, 1038
Paulus, M.P, 473
Pauly, J.R., 224
Pauwels, P.J., 873
Pavan, B., 672
Pazos, A, 93
Pearce, R.A., 1003
Pei, Q., 893, 903
Perret, J., 125
Pezze, M.-A, 926
Picatoste, F, 171
Pintor, J., 311
Pitkänen, A., 1068
Plaisant, F., 801
Pluteanu, F., 70
Powell, S.B, 473
Pralong, E., 157
Pu, F., 533
Puia, G., 49

Radulovic, J, 1089
Ragan, C.I, 1038
Raiteri, L., 390
Raiteri, M., 390
Rampello, L., 17
Randall, M.E., 275
Rao, S.P., 562
Rasmussen, K, 88
Ravasi, L., 653
Redfern, P.H., 911
Reymann, K.G., 17
Reynolds, D.S., 190
Robberecht, P., 125
Robichaud, M, 554
Rocha, L., 111
Rosahl, T.W., 190, 1031
Rupniak, N.M.J., 516
Russig, H, 926

Saaler-Reinhardt, S., 829
Safa, P., 214
Saghyan, A., 70
Sallinen, J, 882
Salloum, J.B., 592
Sananbenesi, F, 1089
Sanchez, V., 449
Sarri, E, 171
Sattler, D., 524
Saulle, E., 8
Scaccianoce, S., 555
Schaffhauser, H., 562
Scheff, S.W., 224
Scheinin, M, 882
Scheuer, T., 413
Schrick, C, 1089
Schrøder, R.L, 553
Schuepbach, E., 672
Schusdziarra, V., 524
Segura, M.F., 482
Seifert, G., 829
Servitja, J.-M, 171
Severini, C, 117
Sewing, S., 829
Shanley, L.J, 855
Sharp, T., 893
Sharples, C.G.V, 1054
Shieh, K.-R., 940
Shimoji, K., 653
Shirhan, M, 253
Shoaib, M, 1054
Sihra, T.S., 686
Silva, A.P, 282
Sinclair, C.J.D., 155
Singh, A, 1100
Singh, M.E., 264
Sirviö, J, 882
Slater, Y.E., 503
Smith, D., 516
Soin, J., 1107
Sokolova, E, 132
Solís, J.M., 26
Sorensen, S.D, 699
Spampinato, U., 342
Spedding, M., 801
Spiess, J, 1089
Sprakes, M., 893
St John, N., 616
Stanton, J.A., 1031
Steinhäuser, C., 829
Stewart, A., 214
Stocker, M., 829
Stolerman, I.P, 1054
Stone, J.D., 381
Stoop, R., 157
Storr, M., 524
Storto, M., 17
Strøbæk, D, 553
Strømgaard, K., 70
Sun, H., 141

Takahata, H., 49
Tan, M.H, 253
Tavares, R.F., 757
Teo, A.L, 253
Terry, A.V., 381
Thompson, S.A, 994
Tillement, J.-P., 642

Tokutomi, N., 1022
Tominaga, M., 958
Tonini, R, 765
Tordera, R., 893
Tricklebank, M.D., 1047
Tropepi, D., 8
Tsukikawa, H., 541
Tucci, S.A., 367

Unger, L., 1047
Urban, M.O., 983
Urenjak, J., 949
Usherwood, P.N.R., 70

Valdivia, A.C., 503
Vandergriff, J, 88
Varney, M.A., 562, 983
Verbois, S.L., 224
Vertongen, P., 125
Vezina, P, 102
Vivas, N.M, 749
von Eichel-Streiber, C, 171

Waelbroeck, M., 125
Wafford, K.A, 994
Wall, M.J, 56
Walsh, M., 616
Wang, H., 141
Wang, M., 949
Wang, R.Y., 462
Wang, S.J., 686
Warburton, E.C., 40
Watanabe, H., 49
Watanabe, T., 958
Webb, J.K., 516
Wess, J., 653
Whiting, P.J., 190
Whittington, M.A., 864
Winklhofer, M., 829
Wong, J.Y.F., 234
Wong, M.C, 253
Wonnacott, S, 1054
Wozniak, D.F., 739
Wurch, T., 873
Wynick, D., 40

Yamada, M., 653
Yamaguchi, M., 206
Yamantürk, P., 199
Yang, L., 275
Yao, B.B., 773
Yap, E.L, 244
Yarov-Yarovoy, V., 413
Yazawa, S., 958
Ye, J.-H., 493
Yoshitake, S., 206
Yoshitake, T., 206
Young, L.J., 584

Zajac, J.-M., 662
Zetterström, T.S.C., 903
Zini, R., 642
Zizzari, P., 672